Peak Bio, Inc.

Peak Bio, Inc. (Nasdaq: IGNY) is the post-merger operating entity formed when Ignyte Acquisition Corp, a blank-check company sponsored by Ignyte Group that completed its initial public offering in 2021, closed its business combination with Peak Bio, a clinical-stage biopharmaceutical firm developing novel oncology and immunology therapeutics. The Form 10-Q filed in May 2022 reflects the company's quarterly financial position as a de-SPAC entity operating in the healthcare and life sciences sector. Following the business combination, Peak Bio began reporting as a public operating company under the IGNY ticker on Nasdaq. Investors and researchers tracking IGNY's full deal history, warrant activity, and SEC filings can sign up for a free SpacDesk account to access the complete data set.